Immunome Inc., a biotechnology company specializing in novel cancer therapies, has announced the granting of inducement awards to eight new employees as part of its 2024 Inducement Plan. These awards include non-statutory stock options to purchase a total of 117,000 shares of common stock. Each option is priced at $9.28 per share, reflecting the company's closing sales price on September 2, 2025. The options are set to vest over four years, with 25% vesting after one year and the remainder vesting monthly over the subsequent 36 months, contingent on the employees' continued service with the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250904636814) on September 04, 2025, and is solely responsible for the information contained therein.